Tides 2027

Tides 2027 takes place on 26–29 April 2027 at Hynes Convention Center, Boston. It is organised by Informa Connect, and B2DB lists 58 speakers and 236 sessions announced so far.

TIDES USA 2027 is an event on oligonucleotide, peptide, mRNA, genome editing and drug delivery therapeutics, taking place at the Hynes Convention Center in Boston, Massachusetts. It offers more than 200 presentations across concurrent tracks covering discovery, development, CMC/manufacturing and commercialization, alongside workshops, an exhibit floor and networking.

Key facts

Keynote speakers

• Anastasia Khvorova, PhD Professor, RNA Therapeutics Institute, UMass Chan Medical School
• Ashok Bhandari, PhD Executive Vice President, Chief Discovery Officer, Protagonist Therapeutics
• Kiran Musunuru, MD, PhD Barry J. Gertz Professor for Translational Research, Perelman School of Medicine, University of Pennsylvania
• Laura Sepp-Lorenzino, PhD Biotech Executive, Board Member and Industry Advisor, GNMmeds LLC
• Michael Kopach, PhD Associate Vice President, Synthetic Molecule Design and Development, Eli Lilly and Company
• Robert Langer, ScD David H. Koch Institute Professor, Massachusetts Institute of Technology
• Vadim Dudkin, PhD Founding Chief Technology Officer, Soufflé Therapeutics

Speakers (58)

Compiled from the published agenda; speakers can claim and verify their own entry.

• Anastasia Khvorova, PhD Professor, RNA Therapeutics Institute, UMass Chan Medical School
• Ashok Bhandari, PhD Executive Vice President, Chief Discovery Officer, Protagonist Therapeutics
• Kiran Musunuru, MD, PhD Barry J. Gertz Professor for Translational Research, Perelman School of Medicine, University of Pennsylvania
• Laura Sepp-Lorenzino, PhD Biotech Executive, Board Member and Industry Advisor, GNMmeds LLC
• Michael Kopach, PhD Associate Vice President, Synthetic Molecule Design and Development, Eli Lilly and Company
• Robert Langer, ScD David H. Koch Institute Professor, Massachusetts Institute of Technology
• Vadim Dudkin, PhD Founding Chief Technology Officer, Soufflé Therapeutics
• Alla Sigova, PhD Senior Vice President, Platform, CAMP4 Therapeutics
• Andrew Anzalone, MD, PhD Co-Founder and Head of Platform, Prime Medicine
• Carolyn Mazzitelli, PhD Executive Director, Ionis Pharmaceuticals
• Dan Appella, PhD Senior Investigator, NIDDK, NIH
• Daphne Schaerlaeckens Scientific Lab Technician, Aspen Oss
• David J. Craik, PhD Professor of Biomolecular Structure, University of Queensland
• Devan Shah RNAv8 Bio
• Elissa Hobert, PhD Senior Director of Discovery Technologies, Souffle Therapeutics
• Eric Fang, PhD General Manager and Site Head, Snapdragon Chemistry, a Cambrex Company
• Fernando Albericio, PhD Research Professor, School of Chemistry, University of Kwazulu-Natal
• Florence Brunel, PhD Senior Principal Scientist, Novo Nordisk
• Fran Wincott, PhD President, Wincott & Associates, LLC
• Ian Huggins, PhD Senior Director, Delivery Services, Aerska
• Ivan Zlatev, PhD Executive Director of Research, Alnylam Pharmaceuticals
• Jane Grogan, PhD Executive Vice President & Head of Research, Biogen
• John Finn, PhD Chief Scientific Officer, Basecamp Research
• John Maraganore, PhD Founding CEO, Alnylam & CEO and Principal, JMM Innovations, LLC
• John Zuris, PhD Principal, John Zuris Consulting LLC
• Julia Alterman, Ph.D. Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Chan Medical
• Kaijiong Xiao, PhD Principal Scientist, Process Research & Development, Merck
• Kathryn Ackley, PhD CMC Consultant Specializing in Oligonucleotides, Independent Consultant
• Kevin Cole, PhD Executive Director, Bioproduct Research and Development, Eli Lilly and Company
• Kristy Wood, PhD Senior Vice President, Technical Operations, Intellia Therapeutics
• Li Xiao, PhD Director, Synthetic Molecule Design & Development, Eli Lilly and Company
• Lin Guey, PhD Chief Scientific Officer, Therapeutics Research, Moderna
• Lori Troup Director of Analytical Development, Novo Nordisk
• Louise Dalboge, PhD Chief Scientific Officer, Gubra Biotech
• Luis Brito, PhD Vice President, Delivery Platform, Beam Therapeutics
• Maged Darwish, PhD Vice President, Global Regulatory Affairs, CMC, Alnylam Pharmaceuticals
• Marc Jacob, PhD Head of Strategic Development, Chromatography Products, YMC America
• Matteo Villain, PhD Vice President of Peptides and Oligonucleotides, Veranova
• Mike Webb, Ph.D. Founder and CEO, Mike Webb Pharma
• Muthiah (Mano) Manoharan, PhD Senior Vice President of Drug Innovation and Distinguished Research Scientist, Alnylam Pharmaceuticals
• Patrick C. Reid, PhD President and CEO, PeptiDream, Inc.
• Patrick Knerr, PhD Vice President, Metabolic Translational Research, Indiana Biosciences Research Institute
• Ranganath Gopalakrishnan, PhD Senior Director and Senior Principal Scientist, Zealand Pharma
• Raquel P. Deering, PhD Executive Director, Cancer Vaccine Research, Moderna
• Ratmir Derda, PhD Founder and CSO, 48 Hour Discovery, University of Alberta
• Roman Hillebrand, PhD Co-founder and CTO/COO, OligoStream Industries
• Rowshon Alam, PhD Vice President, Head of Chemistry, Prime Medicine
• Rubina Parmar, PhD, Atlas Ventures
• Saul Martinez Montero, PhD Executive Director, RNA Therapeutics, Dyne Therapeutics
• Seth Alexander, PhD Director, Enterprise AI, Prime Medicine
• Simona Serban, PhD Global Applications Director, Life Sciences, Sunresin
• Steven Wolk, PhD Founder and Chief Consultant, Sinawali Biotechnology Solutions
• Tina Boville, PhD CEO, Aralez Bio
• Todd Maloney, PhD Associate Vice President of Analytical Chemistry, Eli Lilly & Company
• Troels Koch, PhD Chief Technology Officer, Cora Biosciences
• William Fang Vice President of Oligonucleotide and Peptide Development, WuXi TIDES
• William Kiesman, PhD Chief Technology Officer, Judo Bio
• Yogesh S. Sanghvi, PhD President, Rasayan Inc.

Most represented companies

• Alnylam Pharmaceuticals — 3 speakers
• Eli Lilly and Company — 3 speakers
• Prime Medicine — 3 speakers
• Moderna — 2 speakers
• Novo Nordisk — 2 speakers

Agenda (236 sessions)

Day 1 — Monday 26 April 2027

• Analytical Strategies for Quantifying Lipid-Conjugated Oligo, GalNAc-Conjugated siRNA, and Antisense Oligonucleotide Therapeutics via Solid Phase Extraction Coupled with LC-MS 08:30–09:00 · Breakfast Spotlight Presentations 3
• Purification of TIDES Molecules with Reverse Phase and Anion Exchange Chromatography 08:30–09:00 · Breakfast Spotlight Presentations 1
• Evolution of Ion Exchange Chromatography into a High-Performance Platform for Oligonucleotide Purification 08:30–09:00 · Breakfast Spotlight Presentations 2
• Workshop Leaders’ Welcome and Opening Remarks 09:00–09:10 · Workshop AM3: Chemistries Enabling Oligonucleotide Conjugates
• Workshop Leaders' Welcome and Opening Remarks 09:00–09:05 · Workshop AM1: Introduction to Therapeutic Oligonucleotides - Design, Function and Delivery
• Workshop Leader’s Welcome and Opening Remarks 09:00–09:10 · Workshop AM4: The Next Wave of Innovation in Peptide Manufacturing Technologies
• Workshop Leaders’ Welcome and Opening Remarks 09:00–09:10 · Workshop AM2: Implementation of Novel Paradigms for the Manufacture of Synthetic Oligonucleotides
• Introduction to Therapeutic Oligonucleotides As a New Drug Class 09:05–09:30 · Workshop AM1: Introduction to Therapeutic Oligonucleotides - Design, Function and Delivery
• Design Considerations for Antibody–Oligonucleotide Conjugates: Focusing on Protein Engineering, Bioconjugation Chemistry, and Conjugation Site Selection 09:10–09:40 · Workshop AM3: Chemistries Enabling Oligonucleotide Conjugates
• Enzymatic Ligation: A Next‑Generation Process for siRNA Manufacturing 09:10–09:40 · Workshop AM2: Implementation of Novel Paradigms for the Manufacture of Synthetic Oligonucleotides
• Therapeutic Oligonucleotide Design 09:30–10:00 · Workshop AM1: Introduction to Therapeutic Oligonucleotides - Design, Function and Delivery
• Strategies for Demonstrating Comparability of Oligonucleotide Therapeutics Following Manufacturing Changes 09:40–10:10 · Workshop AM2: Implementation of Novel Paradigms for the Manufacture of Synthetic Oligonucleotides
• Nature-Inspired Continuous N-C Chain Elongation Enables Sustainable Peptide Manufacturing 09:40–10:10 · Workshop AM4: The Next Wave of Innovation in Peptide Manufacturing Technologies
• Nucleic Acid Conjugates: Remote Control, Targeting, and Entirely New Functions 09:40–10:10 · Workshop AM3: Chemistries Enabling Oligonucleotide Conjugates
• Preclinical Considerations 10:00–10:30 · Workshop AM1: Introduction to Therapeutic Oligonucleotides - Design, Function and Delivery
• Major Progress in the Liquid-Phase Synthesis of N-Alkyl-Rich Cyclic Peptides: Kilogram-Scale GMP Production of LUNA18 10:10–10:40 · Workshop AM4: The Next Wave of Innovation in Peptide Manufacturing Technologies
• Fully Liquid Phase, Membrane-Assisted Oligonucleotide Synthesis 10:10–10:40 · Workshop AM2: Implementation of Novel Paradigms for the Manufacture of Synthetic Oligonucleotides
• Chemistry at the Interface of Nucleic Acid (Bio)conjugation 10:10–10:40 · Workshop AM3: Chemistries Enabling Oligonucleotide Conjugates
• Formulation Design 11:00–11:30 · Workshop AM1: Introduction to Therapeutic Oligonucleotides - Design, Function and Delivery
• Development of Enzymatic Strategies for Oligonucleotide Manufacturing 11:10–11:40 · Workshop AM2: Implementation of Novel Paradigms for the Manufacture of Synthetic Oligonucleotides
• Modification of Oligonucleotides at Phosphorus 11:10–11:40 · Workshop AM3: Chemistries Enabling Oligonucleotide Conjugates
• Optimizing GAP Peptide Synthesis for Tirzepatide Fragments 11:10–11:40 · Workshop AM4: The Next Wave of Innovation in Peptide Manufacturing Technologies
• Clinical Considerations 11:30–12:00 · Workshop AM1: Introduction to Therapeutic Oligonucleotides - Design, Function and Delivery
• Chemical Engineering of Conjugated siRNAs for Pharmacokinetic Control 11:40–12:10 · Workshop AM3: Chemistries Enabling Oligonucleotide Conjugates
• Biomanufacturing Therapeutic Peptides at Scale with an Expanded Genetic Code 11:40–12:10 · Workshop AM4: The Next Wave of Innovation in Peptide Manufacturing Technologies
• Regulatory Strategy for Chemoenzymatic siRNA Manufacturing Process 11:40–12:10 · Workshop AM2: Implementation of Novel Paradigms for the Manufacture of Synthetic Oligonucleotides
• Oligonucleotide Manufacture and Control 12:00–12:30 · Workshop AM1: Introduction to Therapeutic Oligonucleotides - Design, Function and Delivery
• Panel Discussion with Workshop Speakers 12:10–12:30 · Workshop AM2: Implementation of Novel Paradigms for the Manufacture of Synthetic Oligonucleotides
• Panel Discussion with Workshop Speakers 12:10–12:30 · Workshop AM3: Chemistries Enabling Oligonucleotide Conjugates
• Panel Discussion with Workshop Speakers 12:10–12:30 · Workshop AM4: The Next Wave of Innovation in Peptide Manufacturing Technologies
• A Modular mRNA–LNP Platform for Targeted In Vivo CAR-T Cell Engineering Using Linear and Circular RNA 12:45–13:15 · Spotlight Presentation Luncheon 2
• Innovative Peptide Manufacturing Methods That Scale 12:45–13:15 · Spotlight Presentation Luncheon 1
• A T7 Toolbox for Molecule-Aware mRNA Manufacturing 12:45–13:15 · Spotlight Presentation Luncheon 3
• Workshop Leaders' Welcome and Opening Remarks 13:30–13:35 · Workshop PM3: In Vivo Genome Editing: Targeted Delivery & Large Gene Knock-ins
• Workshop Leader’s Welcome and Opening Remarks 13:30–13:35 · Workshop PM4: Optimizing the Final Isolation Step of Peptide API
• Workshop Leader's Welcome and Opening Remarks 13:30–15:00 · Workshop PM2: Introduction to Analytical Control Strategies for Therapeutic Oligonucleotides
• Workshop Leader’s Welcome and Opening Remarks 13:30–13:40 · Workshop PM1: CMC and Nonclinical Strategies for an Oligonucleotide Phase 1 IND
• A Lyophilization Roadmap for Peptides 13:35–14:10 · Workshop PM4: Optimizing the Final Isolation Step of Peptide API
• Targeted Delivery: Basic Designs and Places to Go 13:35–14:15 · Workshop PM3: In Vivo Genome Editing: Targeted Delivery & Large Gene Knock-ins
• Nonclinical Development of Oligonucleotides: Integrating Pharmacology, Toxicology, and Pharmacokinetics to Support Early Clinical Development 13:40–14:25 · Workshop PM1: CMC and Nonclinical Strategies for an Oligonucleotide Phase 1 IND
• Enabling Drug Delivery for Peptides Across Multiple Modalities Utilizing the Spray Drying Process 14:10–14:45 · Workshop PM4: Optimizing the Final Isolation Step of Peptide API
• Targeted Delivery for In Vivo CAR-T: Current State and Recent Progress 14:15–15:00 · Workshop PM3: In Vivo Genome Editing: Targeted Delivery & Large Gene Knock-ins
• Manufacturing Aspects of an IND 14:25–15:00 · Workshop PM1: CMC and Nonclinical Strategies for an Oligonucleotide Phase 1 IND
• Process Approach in Electrostatic Drying of Peptides 14:45–15:20 · Workshop PM4: Optimizing the Final Isolation Step of Peptide API
• Workshop PM2: Introduction to Analytical Control Strategies for Therapeutic Oligonucleotides 15:30–17:00 · Workshop PM2: Introduction to Analytical Control Strategies for Therapeutic Oligonucleotides
• Large Knock-ins (Exons and Whole Genes): Current State and Recent Progress 15:30–16:15 · Workshop PM3: In Vivo Genome Editing: Targeted Delivery & Large Gene Knock-ins
• Quality and Regulatory Aspects of an IND 15:30–16:15 · Workshop PM1: CMC and Nonclinical Strategies for an Oligonucleotide Phase 1 IND
• Developing Robust and Scaleable Peptide Precipitation Processes 15:50–16:25 · Workshop PM4: Optimizing the Final Isolation Step of Peptide API
• Targeted Delivery & Large Gene Knock-ins in the Therapeutic Space: Acquisitions, Patents, and Trials 16:15–17:00 · Workshop PM3: In Vivo Genome Editing: Targeted Delivery & Large Gene Knock-ins
• Panel Discussion and Ask the Consultants 16:15–17:00 · Workshop PM1: CMC and Nonclinical Strategies for an Oligonucleotide Phase 1 IND
• Solid Form Strategies for Screening, Crystallization and Purification of Peptides: Vancomycin, a Case Study 16:25–17:00 · Workshop PM4: Optimizing the Final Isolation Step of Peptide API

Day 2 — Tuesday 27 April 2027

• Balanced Approaches to Peptide CMC 07:30–08:00 · Breakfast Spotlight Presentations 1
• The Convergence of Three Novel Downstream Technologies: One Breakthrough in Peptide and Oligonucleotide API Manufacturing 07:30–08:00 · Breakfast Spotlight Presentations 3
• Operational Optimization: Maximizing Synthesizer Performance, Reliability, and Longevity 07:30–08:00 · Breakfast Spotlight Presentations 2
• Chairperson’s Remarks: Keynote Day 1 08:10–08:15 · Keynote and Plenary Session
• Retatrutide: A Breakthrough Triagonist Uniting Molecular Design and Sustainable Manufacturing 08:15–09:00 · Keynote and Plenary Session — Michael Kopach, PhD
• Precision Peptides, Powerful Impact: Protagonist Story of Peptide Innovation from Platform to Patients 09:00–09:45 · Keynote and Plenary Session — Ashok Bhandari, PhD
• The History and Future of Oligonucleotide Manufacturing 10:15–11:00 · Keynote and Plenary Session
• Chemical Innovation in RNAi: From Chemistry to Neurotherapeutic Applications 11:00–11:45 · Keynote and Plenary Session — Anastasia Khvorova, PhD
• Analytical Analysis of Lipid-Conjugated Oligonucleotides: A Balancing Act 12:05–12:35 · Spotlight Presentation Luncheon 1
• Innovating RNA Analytics for Tomorrow’s Therapies 12:05–12:35 · Spotlight Presentation Luncheon 6
• Supporting Clients from Pre-Clinic to Commercial: Using the Wigman Model to Strategize GMP Process Development 12:05–12:35 · Spotlight Luncheon Presentation 5
• Scaling Next-Generation Oligonucleotide Therapeutics Through Vertical Integration and Chemoenzymatic Ligation 12:05–12:35 · Spotlight Presentation Luncheon 3
• Improving CRISPR Genome Editing Efficiency by Optimized Manufacturing Methods for High-purity Modified gRNAs 12:05–12:35 · Spotlight Presentation Luncheon 4
• Impact of Metabolites and Diastereomeric Ratio on Inclisiran’s Potency 12:05–12:35 · Spotlight Presentation Luncheon 2
• Chairperson’s Remarks: Keynote Day 1 12:55–13:00 · Keynote and Plenary Session
• From Nanotechnology to Nucleic Acid Therapeutics: How Overcoming Skepticism and Barriers Led to New Cancer Treatments and Ways to Tackle a Global Health Challenge 13:00–13:45 · Keynote and Plenary Session — Robert Langer, ScD
• From Sequence to Therapy: Innovations in Oligonucleotide and Genome Editing Medicines 13:45–14:30 · Keynote and Plenary Session — Laura Sepp-Lorenzino, PhD
• Novel Ligands for Cell Selective Gene Silencing 15:30–16:15 · Keynote and Plenary Session — Vadim Dudkin, PhD
• Lessons Learned from a Personalized CRISPR Gene Editing Therapy 16:15–17:00 · Keynote and Plenary Session — Kiran Musunuru, MD, PhD

Day 3 — Wednesday 28 April 2027

• TIDES Fun Run & Walk 06:30–07:30 · Fun Run
• Mastering Manufacturing Challenges in Oligonucleotide Production – From Process Development to Commercial Solutions 07:45–08:15 · Breakfast Spotlight Presentations 1
• Unlocking Scalable and Process-Efficient Oligonucleotide Manufacturing: AJIPHASE and Enzymatic Ligation 07:45–08:15 · Breakfast Spotlight Presentations 2
• Overcoming Scale-Up Barriers: Ensuring Robust CMC for Next-Gen Peptide and Oligonucleotide Drugs 07:45–08:15 · Breakfast Spotlight Presentations 3
• Chairman’s Remarks 08:25–08:30 · Peptide Discovery to CMC
• Co-Chairs' Remarks 08:25–08:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Chairwoman’s Remarks 08:25–08:30 · Delivery of Macromolecules
• Chairman’s Remarks 08:25–08:30 · mRNA & Genome Editing: Technology & Applications
• Chairman’s Remarks 08:25–08:30 · Oligonucleotide Chemistry, Manufacturing and Controls
• Novel Peptide Ligands and Therapeutic Applications 08:30–09:00 · Peptide Discovery to CMC
• Carbohydrate-Free Synthesis of Nucleosides and Nucleoside Analogues 08:30–09:00 · Oligonucleotide Chemistry, Manufacturing and Controls
• TfR-mediated Delivery of Oligonucleotides to the Deep Brain Using the VECTrans® Platform: Initial Learnings and Perspectives 08:30–09:00 · Delivery of Macromolecules
• Conditionally Activated siRNA: Precision RNA Therapeutics through Cell-specific Activation 08:30–09:00 · Oligonucleotide Discovery, Preclinical and Clinical
• Transformative LDL Cholesterol Lowering In Vivo CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease 08:30–08:55 · mRNA & Genome Editing: Technology & Applications
• Toward In Vivo Genetic Medicines with Site-specific Integration of Therapeutically Relevant Genes Via an RNA-only Platform 08:55–09:20 · mRNA & Genome Editing: Technology & Applications
• Biomanufacturing of Modified Nucleoside-5′-triphosphates (5´-NTP) as Building-blocks for the Enzymatic Assembly of Oligonucleotides 09:00–09:30 · Oligonucleotide Chemistry, Manufacturing and Controls
• Advancing ADAR RNA Editing Technology for Broad Applicability in Precision Medicines 09:00–09:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Brain Delivery of Antibody-oligonucleotide Conjugates for CNS Diseases 09:00–09:30 · Delivery of Macromolecules
• AI and NCAA to Unlock the Design of Peptide Drugs 09:00–09:30 · Peptide Discovery to CMC
• Development of Bespoke Genome Editing Technologies to Treat Disease 09:20–09:45 · mRNA & Genome Editing: Technology & Applications
• Leveraging IGF1R Receptor for Antisense Delivery 09:30–10:00 · Delivery of Macromolecules
• Biocatalytic Approaches to Nucleic Acid Therapeutics Manufacturing 09:30–10:00 · Oligonucleotide Chemistry, Manufacturing and Controls
• Computational Pipelines for Rational Design of Peptide Macrocycle Therapeutics: Past, Present, and Future 09:30–10:00 · Peptide Discovery to CMC
• From Discovery toward the Clinic: Translational Development of an ASO Targeting a Cardiac Myofibroblast-specific LncRNA 09:30–10:00 · Oligonucleotide Discovery, Preclinical and Clinical
• A Family and Patient Perspective on the Urgent Need for Effective Treatments for Ultra-rare Genetic Conditions 09:45–10:00 · mRNA & Genome Editing: Technology & Applications
• Bringing Method to the Mid-Size Molecule Manufacturing Madness 10:05–10:15 · TIDES Talks in Poster and Exhibit Hall
• A Mild Cleavage and Deprotection Method for RNA Oligonucleotides Synthesized on Universal Supports 10:15–10:25 · TIDES Talks in Poster and Exhibit Hall
• Superior Ligation Solutions for Scalable RNA Manufacturing 10:25–10:35 · TIDES Talks in Poster and Exhibit Hall
• A Novel Ligase for Modified Oligonucleotide Synthesis 10:35–10:45 · TIDES Talks in Poster and Exhibit Hall
• Engineering Cyclotides as Orally Bioavailable Inflammatory Cytokine Antagonists 10:45–11:15 · Peptide Discovery to CMC
• Applying Machine Learning to Identify Differentiated Target Mechanisms and Design Next-Generation Oligonucleotide Therapeutics 10:45–11:15 · mRNA & Genome Editing: Technology & Applications
• Precision RNA Editing at Scale: Platform Innovations Generating Product Candidates 10:45–11:15 · Oligonucleotide Discovery, Preclinical and Clinical
• Progress on Next Generation siRNA Manufacturing Process Development 10:45–11:15 · Oligonucleotide Chemistry, Manufacturing and Controls
• Beyond the Standard: Advancing TfR-Mediated Delivery of Oligonucleotide Therapeutics to the CNS 10:45–11:15 · Delivery of Macromolecules
• Spatial Structured Oligonucleotides for RNA Therapeutics 11:15–11:45 · Oligonucleotide Discovery, Preclinical and Clinical
• BoltzGen: Toward Universal Binder Design 11:15–11:45 · Peptide Discovery to CMC
• Delivery of Gene Writers to Hematopoetic Stem Cells towards an In Vivo Therapy for Sickle Cell Disease 11:15–11:45 · mRNA & Genome Editing: Technology & Applications
• Unlocking the Therapeutic Potential of Oligonucleotides for CNS Disorders Through Targeted Delivery 11:15–11:45 · Delivery of Macromolecules
• GMP Manufacturing of An Oligonucleotide Containing the Mesylphosphoramidate Chemistry 11:15–11:45 · Oligonucleotide Chemistry, Manufacturing and Controls
• Bridging the Divide: Leveraging the Transport Vehicle Platform to Deliver Enzyme, Antibody, and Oligonucleotide-based Therapeutics across the BBB 11:45–12:15 · Delivery of Macromolecules
• Towards Fully Liquid Phase Chemical Synthesis for Efficient Oligonucleotide Manufacturing 11:45–12:15 · Oligonucleotide Chemistry, Manufacturing and Controls
• Improving the Potency and Specificity of RNAi Therapeutics: Carbocyclic DNA and RNA Modifications 11:45–12:15 · Oligonucleotide Discovery, Preclinical and Clinical
• ADAPT: An Emerging Platform of Antibody CDR-H3 Peptide Scaffolds in the Landscape of Protein-Protein Interaction Inhibitors 11:45–12:15 · Peptide Discovery to CMC
• Precise, RNA-mediated Insertion of Transgenes Using an R2 Retrotransposase Yields Stable, Durable, and Therapeutic Hepatic Protein Expression, From Mice to NHPs 11:45–12:15 · mRNA & Genome Editing: Technology & Applications
• Beyond Capacity: Rethinking Oligonucleotide Development and Manufacturing for Next-Generation Modalities 12:20–12:50 · Spotlight Presentation 3
• Accelerate Timeline to Start PhI: Phase Appropriate Development and Integrated Drug Product Supply 12:20–12:50 · Spotlight Presentation 5
• Advances in LC Separations, MS Detection, and Statistical Analyses for Characterizing Oligonucleotide Therapeutics for Advancing New and Generic Drug Development 12:20–12:50 · Spotlight Presentation 2
• Stirring Things Up: Integrating Stirred-Bed SPOS and Enzymatic Ligation for Industrial Oligonucleotide Production 12:20–12:50 · Spotlight Presentation 1
• OCELOT®: The Open, Unified Software Platform for Modern Oligo Manufacturing 12:20–12:50 · Spotlight Presentation 4
• Overcoming Barriers to Oral Delivery of Macromolecules Through Innovative Technologies 13:00–13:10 · TIDES Talks in Poster and Exhibit Hall
• Artificial Intelligence and Machine Learning for accelerating peptide drug discovery 13:10–13:20 · TIDES Talks in Poster and Exhibit Hall
• Membrane Applications in Oligonucleotide Synthesis 13:20–13:30 · TIDES Talks in Poster and Exhibit Hall
• FISTag: A New Tool in the LPPS Arena 13:30–13:40 · TIDES Talks in Poster and Exhibit Hall
• Innovating Oligonucleotide Production: Chemoenzymatic Synthesis 13:40–13:50 · TIDES Talks in Poster and Exhibit Hall
• Co-Chairs' Remarks 13:55–14:00 · mRNA & Genome Editing: Technology & Applications
• Chairman’s Remarks 13:55–14:00 · Delivery of Macromolecules
• Chairman’s Remarks 13:55–14:00 · Oligonucleotide Chemistry, Manufacturing and Controls
• Co-Chairs’ Remarks 13:55–14:00 · Peptide Discovery to CMC
• Chairwoman's Remarks 13:55–14:00 · Oligonucleotide Discovery, Preclinical and Clinical
• From Process Development to GMP Scale: Advancing Enzymatic Ligation for Oligonucleotide Therapeutics 14:00–14:30 · Oligonucleotide Chemistry, Manufacturing and Controls
• Efficient Modification Chemistry for RNA Stabilization and Control 14:00–14:30 · mRNA & Genome Editing: Technology & Applications
• Utilization of Oligonucleotides’ Half-Life to Optimize Dosing Regimen for Desirable Efficacy & Reduced CNS Toxicity 14:00–14:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Novel e-pHLIP Technology for Cytoplasmic Delivery of Polar Molecules 14:00–14:30 · Delivery of Macromolecules
• PN-881: A Next-Generation Oral IL-17 Antagonist Redefining Peptide Immunotherapy 14:30–15:00 · Peptide Discovery to CMC
• New SPOS Support to Drive Next Generation Manufacturing 14:30–15:00 · Oligonucleotide Chemistry, Manufacturing and Controls
• Discovering Novel Receptor Portals for Oligonucleotide Delivery via Multiplexed In Vivo Screening 14:30–15:00 · Delivery of Macromolecules
• Beyond Codons: The Structural and Regulatory Logic Governing mRNA Translation 14:30–15:00 · mRNA & Genome Editing: Technology & Applications
• Investigational RNAi Therapeutics in Development for CNS Diseases 14:30–15:00 · Oligonucleotide Discovery, Preclinical and Clinical
• In Vivo Generation of Functional CD8+ CAR T-Cells and Renal Gene Editing Driven by Distinct and Selective LNP Tropism 15:00–15:30 · Delivery of Macromolecules
• Analytical Platform Technologies for mRNA-based Therapeutics and Vaccines 15:00–15:30 · mRNA & Genome Editing: Technology & Applications
• Cellular Correlates of Oligonucleotide-induced Neurotoxicity 15:00–15:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Rethinking Oligonucleotide Synthesis: A Rapid Continuous-Flow Approach Enabled by Convergent Liquid-Phase Chemistry and DoE 15:00–15:30 · Oligonucleotide Chemistry, Manufacturing and Controls
• Early Development Strategies for Peptide Therapeutics 15:00–15:30 · Peptide Discovery to CMC
• Create the Perfect mRNA for Translation in Cells 15:35–15:45 · TIDES Talks in Poster and Exhibit Hall
• An Ionizable LNP Platform for Scalable in vivo CAR T Cell Engineering 15:45–16:05 · TIDES Talks in Poster and Exhibit Hall
• OmniUltra™: A Dual Modality in vivo Discovery Platform for Novel Human Antibodies and Structured Peptides 16:05–16:15 · TIDES Talks in Poster and Exhibit Hall
• Deep Learning-based Design of Cell-targeting Ligands Enables Functional siRNA Delivery in Multiple Extrahepatic Tissues 16:15–16:45 · Delivery of Macromolecules
• Advancing Sustainability through Innovation in Oligonucleotide Manufacturing 16:15–16:45 · Oligonucleotide Chemistry, Manufacturing and Controls
• Unlocking Macrocyclic Peptides for Challenging Drug Targets 16:15–16:45 · Peptide Discovery to CMC
• FORCE Platform to Enable Delivery of Oligonucleotides for the Treatment of Neuromuscular Diseases 16:15–16:45 · Oligonucleotide Discovery, Preclinical and Clinical
• Self-replicating RNA (srRNA) Vaccines Using Unmodified Bases Show An Expanded Clinical Therapeutic Index and Sustained Immune Responses 16:15–16:45 · mRNA & Genome Editing: Technology & Applications
• Pushing the Efficiency and Scale of Enzymatic RNA Synthesis 16:45–17:15 · Oligonucleotide Chemistry, Manufacturing and Controls
• Targeting Tumors with Peptide Radioconjugates 16:45–17:15 · Peptide Discovery to CMC
• Activating Anti-tumor Immunity with RNA/DNA Hybrid Agonists of TLR7/8/9 16:45–17:15 · Oligonucleotide Discovery, Preclinical and Clinical
• Advancing RNA Therapeutics through Process Innovation: mRNA and LNP Technologies Shaping the Future of in vivo CAR T Therapies 16:45–17:15 · mRNA & Genome Editing: Technology & Applications
• Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM™ SC 16:45–17:15 · Delivery of Macromolecules
• Enabling Next-Generation mRNA Therapeutics Through a Cell-Based mRNA Design and Manufacturing Platform 17:15–17:45 · mRNA & Genome Editing: Technology & Applications
• Targeting the Lung, One Breath at a Time: The Great Promise of Splisense’s ASO Therapeutic Platform to Tackle a Wide Range of Pulmonary Diseases 17:15–17:45 · Oligonucleotide Discovery, Preclinical and Clinical
• A Non-Viral Platform for Subcutaneous DNA Delivery and Durable In Vivo Protein Expression 17:15–17:45 · Delivery of Macromolecules
• Enzymatic Approaches to Oligonucleotide Manufacture 17:15–17:45 · Oligonucleotide Chemistry, Manufacturing and Controls
• Discovery of 225Ac-ETN029: A Peptide-based Radioligand Therapy for the Treatment of DLL3-expressing Solid Tumors 17:15–17:45 · Peptide Discovery to CMC

Day 4 — Thursday 29 April 2027

• Offsite Boxing Fitness Class - Reservation Required 06:30–07:30 · Fitness Class
• Manufacturing of Next-Generation Antibody–Oligonucleotide Conjugates through Versatile Bioconjugation Strategies 07:45–08:15 · Breakfast Spotlight Presentations 3
• Advancing mRNA Therapeutics: AI-driven mRNA Design and Novel Modification Strategies for Improved Performance 07:45–08:15 · Breakfast Spotlight Presentations 2
• LNP-production for mRNA-vaccines, Therapeutics and for Gene-editing – Proof of Concept for a Versatile Process 07:45–08:15 · Breakfast Spotlight Presentations 1
• Co-Chairs' Remarks 08:25–08:30 · Peptide Discovery to CMC
• Chairman's Remarks 08:25–08:30 · mRNA & Genome Editing: Technology & Applications
• Chairwoman’s Remarks 08:25–08:30 · Delivery of Macromolecules
• Chairman’s Remarks 08:25–08:30 · Oligonucleotide Chemistry, Manufacturing and Controls
• Chairman’s Remarks 08:25–08:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Next-Generation RNA Medicines 08:30–09:00 · Oligonucleotide Discovery, Preclinical and Clinical
• Insights into mRNA Higher-Order Structure and Impact on Integrity Analyses 08:30–09:00 · mRNA & Genome Editing: Technology & Applications
• Chemically Convergent Peptide Synthesis: Eliminating SPPS and the Impact on Registered Starting Material Designations 08:30–09:00 · Peptide Discovery to CMC
• Controlling Phosphorothioate Stereochemistry: Challenges and Innovations in Oligonucleotide Manufacturing 08:30–09:00 · Oligonucleotide Chemistry, Manufacturing and Controls
• Novel Extrahepatic RNAi Therapeutics for Obesity Targeting Adipocytes and Skeletal Muscle via the LEAD™ Technology 08:30–09:00 · Delivery of Macromolecules
• Characterization of mRNA Using Liquid Chromatography and Mass Spectrometry 09:00–09:30 · mRNA & Genome Editing: Technology & Applications
• The Strike Platform Enables Kidney-Selective Gene Silencing 09:00–09:30 · Delivery of Macromolecules
• SpiNA siRNA Design Enables Durable Silencing of Inhbe RNA and Fat Loss without Muscle Loss in a Mouse Model of Obesity 09:00–09:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Validation Without the Guesswork: A Fit-for-Purpose Strategy for Oligonucleotide Manufacturing 09:00–09:30 · Oligonucleotide Chemistry, Manufacturing and Controls
• A Mild and Sustainable Platform for Disulfide Bond Formation in Peptide Manufacturing Using Dehydroascorbic Acid 09:00–09:30 · Peptide Discovery to CMC
• Rethinking the Oligonucleotide Backbone: A New Approach to RNA Therapeutic Design 09:30–10:00 · Oligonucleotide Discovery, Preclinical and Clinical
• Direct RNA Sequencing to Study mRNA Therapeutics and Their Metabolism 09:30–10:00 · mRNA & Genome Editing: Technology & Applications
• Development of a Multi-Enzyme Cascade En-Route to Enlicitide (MK-0616) 09:30–10:00 · Peptide Discovery to CMC
• Introducing Chemical Ligation for siRNA manufacturing 09:30–10:00 · Oligonucleotide Chemistry, Manufacturing and Controls
• siRNA CNS Delivery Using Peptide Ligands and Preclinical Development 09:30–10:00 · Delivery of Macromolecules
• TIDES Talk 10:05–10:15 · TIDES Talks in Poster and Exhibit Hall
• Enabling the Scale-Up of Custom Nucleic Acid Chemistries from Development to Commercial Supply 10:15–10:35 · TIDES Talks in Poster and Exhibit Hall
• From Molecule to Market: An Integrated CRDMO Approach for Peptides 10:35–10:45 · TIDES Talks in Poster and Exhibit Hall
• Oleic Acid Conjugation as a Brain Shuttle to Reach Nervous System after IV Injection 10:45–11:15 · Oligonucleotide Discovery, Preclinical and Clinical
• Sequencing-Based Analytics for the Next Generation of mRNA Therapeutics 10:45–11:15 · mRNA & Genome Editing: Technology & Applications
• Peptide Manufacturing Under Pressure: Starting-Material and CDMO Challenges 10:45–11:15 · Peptide Discovery to CMC
• Next-Generation ADC for Targeted Immune Modulation: Oligonucleotide Payloads Differentiate from Cytotoxic Agents 10:45–11:15 · Oligonucleotide Chemistry, Manufacturing and Controls
• Amphiphilic Shuttle Peptide Enables the Development of PMO-based Therapeutics to Treat Basal Cell Carcinoma and Muco-obstructive Lung Diseases 10:45–11:15 · Delivery of Macromolecules
• Enhancing mRNA Translatability and Safety: Suppression of Antisense Transcription via the Nicked Low dsRNA Template (NiLoT) Strategy 11:15–11:45 · mRNA & Genome Editing: Technology & Applications
• Delivering RNAi to Extra-hepatic Tissues 11:15–11:45 · Delivery of Macromolecules
• Driving Time‑to‑Market Excellence: Integrated Lab Innovations and Modular Production Models 11:15–11:45 · Peptide Discovery to CMC
• Targeting Noncoding Regulatory RNAs with Antisense Oligonucleotides to Increase Gene Expression for the Potential Treatment of Haploinsufficient Diseases 11:15–11:45 · Oligonucleotide Discovery, Preclinical and Clinical
• Complementary Liquid Chromatographic and NMR Spectroscopic Approaches to Characterize Phosphorothioate Linkages in siRNA Therapeutics 11:15–11:45 · Oligonucleotide Chemistry, Manufacturing and Controls
• Latest Updates from ANQUR, QurAlis’ Phase 1 Study of QRL-201 for Treatment of ALS 11:45–12:15 · Oligonucleotide Discovery, Preclinical and Clinical
• Discovery and Translation of Extrahepatic Peptides for Oligonucleotide Delivery 11:45–12:15 · Delivery of Macromolecules
• Engineering T7 RNA Polymerase to Reduce Double Stranded RNA Impurities and Improve Capping Efficiency 11:45–12:15 · mRNA & Genome Editing: Technology & Applications
• Please Choose A Different Track 11:45–12:15 · Oligonucleotide Chemistry, Manufacturing and Controls
• Comprehensive Characterization of Peptides and New Modalities Using Multidimensional Chromatography and Mass Spectrometry 11:45–12:15 · Peptide Discovery to CMC
• Tagging the Future: Scalable Biopolymer Production in Solution 12:20–12:50 · Spotlight Presentation 1
• Efficient Conformational Sampling in Nucleic Acids Using LowModeMD 12:20–12:50 · Spotlight Presentation 5
• Revolutionizing Gene Therapeutics through Non-Viral, Tissue-Selective Delivery Platforms 12:20–12:50 · Spotlight Presentation 4
• Stability and Downstream Processing of TIDES and Therapeutics Dried by Electrostatic Drying Technology 12:20–12:50 · Spotlight Presentation 3
• TIDES Talk 12:55–13:05 · TIDES Talks in Poster and Exhibit Hall
• NittoPhase™ SL: A High-Functional-Density Solid Support for Short-Mer Oligonucleotide Production 13:05–13:15 · TIDES Talks in Poster and Exhibit Hall
• Addressing the Acetonitrile Supply by Implementing Recovery and Reuse Strategies 13:15–13:25 · TIDES Talks in Poster and Exhibit Hall
• DMF-Free Synthesis and Purification of GLP-1 RA Using Green Solvents and Catch-and-Release Technology 13:25–13:35 · TIDES Talks in Poster and Exhibit Hall
• Improving siRNA Yield and Manufacturing Performance with PrimeMax™ CPG 13:35–13:45 · TIDES Talks in Poster and Exhibit Hall
• Chairman’s Remarks 13:55–14:00 · Oligonucleotide Discovery, Preclinical and Clinical
• Chairman’s Remark's 13:55–14:00 · mRNA & Genome Editing: Technology & Applications
• Chairman's Remarks 13:55–14:00 · Peptide Discovery to CMC
• Chairwoman’s Remarks 13:55–14:00 · Oligonucleotide Chemistry, Manufacturing and Controls
• Regulatory Expectations for Synthetic Oligonucleotides: Trends, Challenges, and Opportunities 14:00–14:30 · Oligonucleotide Chemistry, Manufacturing and Controls
• Development of an Anti-microRNA Therapy for the Treatment of Myotonic Dystrophy Type 1 - The ArthemiR Clinical Trial 14:00–14:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Expanding the Impact of mRNA Cancer Therapeutics 14:00–14:30 · mRNA & Genome Editing: Technology & Applications
• Oral Delivery of Peptides 14:00–14:30 · Peptide Discovery to CMC
• Practical Application of Platform Approaches for Oligonucleotides 14:30–15:00 · Oligonucleotide Chemistry, Manufacturing and Controls
• Advancing RNAi Therapeutics for Ocular Disorders 14:30–15:00 · Oligonucleotide Discovery, Preclinical and Clinical
• Building Robust Control Strategies for Peptide APIs: From Synthesis to Regulatory Approval 14:30–15:00 · Peptide Discovery to CMC
• Beyond the Needle: Engineering Novel mRNA Lipid Nanoparticle Formulations for Mucosal Vaccination 14:30–15:00 · mRNA & Genome Editing: Technology & Applications
• Advancing Sustainable Peptide Synthesis: Replacing Trifluoroacetic Acid in Global Deprotection 15:00–15:30 · Peptide Discovery to CMC
• In Vivo Transient Programming of T Cells with Targeted Nanoparticles Encapsulating eRNATM-encoded hCD19 CAR Achieves Deep Depletion of B cells in Blood and Lymphoid Tissues 15:00–15:30 · mRNA & Genome Editing: Technology & Applications
• First-in-Class Oligonucleotide Therapy against Metastatic Cancer 15:00–15:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Application of Accelerated Predictive Stability to siRNA Long Term Stability Assessment 15:00–15:30 · Oligonucleotide Chemistry, Manufacturing and Controls
• Terminal Sterilization Strategies for Peptides 16:00–16:30 · Peptide Discovery to CMC
• A Risk-Based Framework for Microbiological Control in Oligonucleotide Drug Substance Manufacturing 16:00–16:30 · Oligonucleotide Chemistry, Manufacturing and Controls
• ADME and Clinical Pharmacology of Olezarsen – a GalNAc-Conjugated Antisense Oligonucleotide 16:00–16:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Developing Analytical Control Strategies for Complex Synthetic Peptides: A Lifecycle‑Focused, Regulatory‑Aligned Approach 16:30–17:00 · Peptide Discovery to CMC
• Expanding RNAi Frontiers with Novel Triggers and Ligands for Extrahepatic Delivery 16:30–17:00 · Oligonucleotide Discovery, Preclinical and Clinical
• Ensuring Diastereomeric Consistency in Phosphorothioate-modified siRNAs: Analytical and Process Strategies for Robust Clinical Development 16:30–17:00 · Oligonucleotide Chemistry, Manufacturing and Controls
• TGM-312: A Novel GalOmic siRNA for the Treatment of MASH 17:00–17:30 · Oligonucleotide Discovery, Preclinical and Clinical
• Development of a HILIC-WAX Two-Dimensional Liquid Chromatography Method for UV-Based Quantitation of Antisense Oligonucleotide Impurities 17:00–17:30 · Oligonucleotide Chemistry, Manufacturing and Controls

Organisers, sponsors and partners

Organiser (1)

Informa Connect

Exhibitors (16)

Thermo Fisher · Entegris · SK pharmteco · PharmaBlock · Agilent Technologies · Biocytogen · Phenomenex · Twist Bioscience · Codexis · Croda Pharma · Gore Inc. · Almac Group · DuPont · Nitto Avecia · Aldevron · Promega

Source: the published agenda. See how B2DB compiles its records.